Receptos Executives Sell Stock After Successful Drug Test

Five executives at Receptos Inc., an immune and metabolic-disease drugmaker that staged an initial public offering last year, sold $36.7 million of stock after the company reported positive results from a drug study that sent shares soaring.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.